Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 7
2004 23
2005 44
2006 45
2007 67
2008 59
2009 70
2010 89
2011 89
2012 132
2013 152
2014 168
2015 189
2016 174
2017 134
2018 124
2019 153
2020 150
2021 138
2022 156
2023 156
2024 56

Text availability

Article attribute

Article type

Publication date

Search Results

2,067 results

Results by year

Filters applied: . Clear all
Page 1
Thyroid Cancer: A Review.
Boucai L, Zafereo M, Cabanillas ME. Boucai L, et al. JAMA. 2024 Feb 6;331(5):425-435. doi: 10.1001/jama.2023.26348. JAMA. 2024. PMID: 38319329 Review.
Targeted therapies such as dabrafenib and selpercatinib are directed to genetic mutations (BRAF, RET, NTRK, MEK) that give rise to thyroid cancer and are used in patients with advanced thyroid carcinoma. ...
Targeted therapies such as dabrafenib and selpercatinib are directed to genetic mutations (BRAF, RET, NTRK, MEK) that give rise to th …
Updates on the Management of Thyroid Cancer.
Araque KA, Gubbi S, Klubo-Gwiezdzinska J. Araque KA, et al. Horm Metab Res. 2020 Aug;52(8):562-577. doi: 10.1055/a-1089-7870. Epub 2020 Feb 10. Horm Metab Res. 2020. PMID: 32040962 Free PMC article. Review.
Among novel patient-tailored therapies are selective RET inhibitors that have shown efficacy in the treatment of MTC with limited systemic toxicity compared with non-specific tyrosine kinase inhibitors. The combination of BRAF and MEK inhibitors have revolutionized managem …
Among novel patient-tailored therapies are selective RET inhibitors that have shown efficacy in the treatment of MTC with limited systemic t …
Molecular genetics and diagnosis of thyroid cancer.
Nikiforov YE, Nikiforova MN. Nikiforov YE, et al. Nat Rev Endocrinol. 2011 Aug 30;7(10):569-80. doi: 10.1038/nrendo.2011.142. Nat Rev Endocrinol. 2011. PMID: 21878896 Review.
Common mutations found in thyroid cancer are point mutation of the BRAF and RAS genes as well as RET/PTC and PAX8/PPARgamma chromosomal rearrangements. ...A potential role of dietary iodine excess in the generation of BRAF point mutations has also been proposed. Som …
Common mutations found in thyroid cancer are point mutation of the BRAF and RAS genes as well as RET/PTC and PAX8/PPARgamma chromosom …
BRAF mutations in thyroid cancer.
Scheffel RS, Dora JM, Maia AL. Scheffel RS, et al. Curr Opin Oncol. 2022 Jan 1;34(1):9-18. doi: 10.1097/CCO.0000000000000797. Curr Opin Oncol. 2022. PMID: 34636352 Review.
RECENT FINDINGS: Despite the unfavorable course associated with PTCs harboring BRAF V600E mutation, its prognostic role remains debated. BRAF V600E-driven tumors exhibit high Extracellular signal-regulated kinase phosphorylation, leading to unregulated cell prolifer …
RECENT FINDINGS: Despite the unfavorable course associated with PTCs harboring BRAF V600E mutation, its prognostic role remains debat …
Molecular Alterations in Thyroid Carcinoma.
Haroon Al Rasheed MR, Xu B. Haroon Al Rasheed MR, et al. Surg Pathol Clin. 2019 Dec;12(4):921-930. doi: 10.1016/j.path.2019.08.002. Epub 2019 Sep 27. Surg Pathol Clin. 2019. PMID: 31672298 Free PMC article. Review.
Constitutional activation of the mitogen-activated protein kinase pathway through RAS mutation, BRAF mutation, and/or fusions involving receptor tyrosine kinase (eg, (REarranged during Transfection) RET-PTC) plays a central role in tumorigenesis and opens doors to promisin …
Constitutional activation of the mitogen-activated protein kinase pathway through RAS mutation, BRAF mutation, and/or fusions involvi …
Risk and Prognostic Factors for BRAF(V600E) Mutations in Papillary Thyroid Carcinoma.
Wei X, Wang X, Xiong J, Li C, Liao Y, Zhu Y, Mao J. Wei X, et al. Biomed Res Int. 2022 May 18;2022:9959649. doi: 10.1155/2022/9959649. eCollection 2022. Biomed Res Int. 2022. PMID: 35647194 Free PMC article. Review.
We aim to investigate the risk factors that may predict the BRAF(V600E) mutation potential of these lesions and new prevention strategies in PTC patients. ...Tumor size (>1 cm) and distant metastasis do not appear to be correlated with BRAF(V600E) mutation in PTC …
We aim to investigate the risk factors that may predict the BRAF(V600E) mutation potential of these lesions and new prevention strate …
Papillary Thyroid Carcinoma: Current Position in Epidemiology, Genomics, and Classification.
Lam AK. Lam AK. Methods Mol Biol. 2022;2534:1-15. doi: 10.1007/978-1-0716-2505-7_1. Methods Mol Biol. 2022. PMID: 35670964
Papillary thyroid carcinomas could occur in familial settings, and 5% of these familial cases have well-studied driver germline mutations. In sporadic papillary thyroid carcinoma, BRAF mutation is common and is associated with clinicopathologic and prognostic markers. ...
Papillary thyroid carcinomas could occur in familial settings, and 5% of these familial cases have well-studied driver germline mutations. I …
Single-cell transcriptomic analysis of the tumor ecosystems underlying initiation and progression of papillary thyroid carcinoma.
Pu W, Shi X, Yu P, Zhang M, Liu Z, Tan L, Han P, Wang Y, Ji D, Gan H, Wei W, Lu Z, Qu N, Hu J, Hu X, Luo Z, Li H, Ji Q, Wang J, Zhang X, Wang YL. Pu W, et al. Nat Commun. 2021 Oct 18;12(1):6058. doi: 10.1038/s41467-021-26343-3. Nat Commun. 2021. PMID: 34663816 Free PMC article.
Along the developmental trajectory, we also discover three phenotypes of malignant thyrocytes (follicular-like, partial-epithelial-mesenchymal-transition-like, dedifferentiation-like), whose composition shapes bulk molecular subtypes, tumor characteristics and RAI responses. Furt …
Along the developmental trajectory, we also discover three phenotypes of malignant thyrocytes (follicular-like, partial-epithelial-mesenchym …
Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era.
Capdevila J, Awada A, Führer-Sakel D, Leboulleux S, Pauwels P. Capdevila J, et al. Cancer Treat Rev. 2022 May;106:102380. doi: 10.1016/j.ctrv.2022.102380. Epub 2022 Mar 15. Cancer Treat Rev. 2022. PMID: 35305441 Free article. Review.
Inhibitors of aberrant proteins resulting from alterations in RET (rearranged during transfection) and BRAF (B-Raf proto-oncogene) have also shown promising efficacy, and so far have received approval by the US Food and Drug Administration. ...
Inhibitors of aberrant proteins resulting from alterations in RET (rearranged during transfection) and BRAF (B-Raf proto-oncogene) ha …
Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.
Nikiforova MN, Mercurio S, Wald AI, Barbi de Moura M, Callenberg K, Santana-Santos L, Gooding WE, Yip L, Ferris RL, Nikiforov YE. Nikiforova MN, et al. Cancer. 2018 Apr 15;124(8):1682-1690. doi: 10.1002/cncr.31245. Epub 2018 Jan 18. Cancer. 2018. PMID: 29345728 Free PMC article.
RESULTS: In the training tissue set of samples, ThyroSeq GC detected more than 100 genetic alterations, including BRAF, RAS, TERT, and DICER1 mutations, NTRK1/3, BRAF, and RET fusions, 22q loss, and gene expression alterations. ...
RESULTS: In the training tissue set of samples, ThyroSeq GC detected more than 100 genetic alterations, including BRAF, RAS, TERT, an …
2,067 results